港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

抗疫概念

935.639

-3.103-0.33%

漲家數：6

跌家數：11

平家數：1

市盈率：- -

高：961.843

開：939.153

低：926.987

收：938.742

資料載入中...

比亞迪總部通宵達旦！一晚上56億美金

奇偶工作室

比亞迪(01211.HK)正式進入哈薩克斯坦市場

阿斯达克财经

科技創新推動新能源車從量變走向質變

经济参考报

與復星醫藥“分手”後，靠阿茲夫定成名的真實生物赴港募資

拉來中東土豪，比亞迪在港融資435億港元

华尔街见闻

恩華藥業(002262.SZ)擬出資350萬美元認購三晟醫藥Pre-A輪優先股1250萬股

恩華藥業：擬出資350萬美元購買三晟醫藥Pre-A輪優先股1250萬股

视频滚动新闻

授權合作獲益、尚無產品上市，和譽醫藥首度實現全年盈利

白雲山子公司《藥品生產許可證》變更

格隆汇资讯

白雲山(00874)：明興藥業收到《藥品生產許可證》

白雲山子公司廣藥總院通過高新技術企業重新認定

白雲山(00874)：廣藥總院通過高新技術企業重新認定

星昊醫藥收盤上漲1.62%，滾動市盈率19.97倍，總市值19.97億元

國家醫保局：國家醫保信息平台累計歸集追溯碼227億條

石藥(01093.HK)：新藥JMT108獲批於中國開展臨牀試驗

阿斯达克财经

石藥集團(01093)開發的I類新藥雙功能融合蛋白藥物JMT108獲中國臨牀試驗批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1515/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":935.6389,"timestamp":1741589963023,"preClose":938.7422,"halted":0,"volume":480654994,"delay":0,"changeRate":-0.003306,"change":-3.103271,"pbRate":1.645833,"amount":4445727246,"amplitude":0.037131,"prevYearClose":787.97723,"fiveDayClose":910.428,"twentyDayClose":879.539,"turnoverRate":0.006521,"marketCap":646601824800,"floatMarketCap":530606604704,"peRate":19.918974},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":961.84296,"amplitude":0.037131,"preClose":938.7422,"low":926.9865,"pbRate":"1.645833","latestPrice":935.6389,"volume":480654994,"delay":0,"open":939.1531,"prevYearClose":787.97723,"prevWeekClose":938.742,"prevMonthClose":904.791,"prevQuarterClose":787.977,"fiveDayClose":910.428,"twentyDayClose":879.539,"sixtyDayClose":794.849,"secType":"PLATE","market":"HK","turnoverRate":0.006521,"peRate":19.918974,"marketCap":646601824800,"floatMarketCap":530606604704,"timestamp":1741589963023,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":6,"down":11,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:16,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517908464","title":"比亞迪總部通宵達旦！一晚上56億美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908464","media":"奇偶工作室","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908464?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 07:59","pubTimestamp":1741219171,"startTime":"0","endTime":"0","summary":"比亚迪创下了，过去十年全球汽车界股权再融资的规模纪录！比亚迪李黔，刚熬了一个开心的通宵。随后，比亚迪全民智驾战略的发布，全球资本对中国应用AI的速度刮目相看。反映在资本市场上，今年以来比亚迪股价涨幅超27%，市值重回万亿人民币大关；而特斯拉股价同期跌幅近30%，市值跌破万亿美元大关。目前比亚迪拥有全球车企中最多的11万工程师，累计研发投入超1600亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306084851a2617517&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306084851a2617517&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516738.SGD","LU0511384066.AUD","LU0052750758.USD","LU0274383008.USD","LU0823426480.USD","LU0348735423.USD","BK1504","LU0449509016.USD","LU0449515922.USD","SG9999001226.SGD","LU0143863198.USD","LU0823414478.USD","LU0823426308.USD","LU2476274308.USD","BK1515","LU0289960550.SGD","LU2097828557.USD","LU0289739343.SGD","BK1594","LU0359202008.SGD","BK1607","BK1582","LU1868837565.USD","01211","LU0856984785.SGD","LU1808992512.USD","HYDD.SI","SG9999006597.SGD","LU0819123356.HKD","LU0348766576.USD","00285","LU0516422952.EUR","LU0593848301.USD","LU0254981946.USD","LU0819121731.USD","SG9999015986.USD","LU2778985437.USD","BK1119","LU2360107325.USD","BYDDY","LU2097828805.USD","LU0320764599.SGD","LU0531970944.HKD","LU1861219969.SGD","BK1589","002594","BK1509","81211","LU2348774022.SGD","IE00BD6J9T35.USD"],"gpt_icon":1},{"id":"2517797910","title":"比亞迪(01211.HK)正式進入哈薩克斯坦市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2517797910","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517797910?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 07:38","pubTimestamp":1741217880,"startTime":"0","endTime":"0","summary":"比亚迪(01211.HK) (002594.SZ) 表示，上月底牵手合作伙伴Astana Motors在哈萨克斯坦阿拉木图和阿斯塔纳召开产品上市发布会，正式进入哈萨克斯坦市场。首批投放市场的车型包括旗舰纯电轿车汉EV和宋PLUS EV & DM-i。(ta/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20241209145116705_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20241209145116705_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1422515&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01211","LU1023057109.AUD","LU0348767384.USD","BK1149","BK1515","LU0211977185.USD","BK1522","LU0254981946.USD","EVS.SI","LU2778985437.USD","LU0052750758.USD","LU0823426480.USD","SG9999015945.SGD","BK0070","LU1868837722.USD","LU0175139822.USD","LU1580142542.USD","LU0214875030.USD","LU0143863198.USD","LU2476274308.USD","BK1504","LU1868838027.USD","LU1146622755.USD","LU2097828557.USD","LU0348805143.USD","002594","LU1808992512.USD","LU0164872284.USD","LU1868837565.USD","SG9999014674.SGD","BK0072","BK1607","LU2153592121.USD","00285","LU0516423091.SGD","IE00BD6J9T35.USD","LU2148510915.USD","LU1861214812.USD","BYDDY","LU1064130708.USD","LU0289961442.SGD","81211","LU2097828714.EUR","BK1610","LU0320764599.SGD","LU0823426308.USD","SG9999015986.USD","LU0819123356.HKD","HYDD.SI","LU1242518931.SGD"],"gpt_icon":0},{"id":"2517279219","title":"科技創新推動新能源車從量變走向質變","url":"https://stock-news.laohu8.com/highlight/detail?id=2517279219","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517279219?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 05:44","pubTimestamp":1741211055,"startTime":"0","endTime":"0","summary":"新一轮科技革命正同时驱动能源与信息两大领域的突破，使新能源汽车产业迎来量变到质变的“奇点”时刻。车企“激战”智能化作为全球汽车产业乃至科技竞争的制高点之一，“智能驾驶”赛道上的争夺日益白热化。3月3日，吉利汽车发布了统一的智能驾驶系统“千里浩瀚”，并规划了H1、H3、H5、H7、H9五个层级的智驾方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503063337640134.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063337640134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0143863784.USD","BK1515","BK1607","LU0348805143.USD","LU1242518857.USD","SG9999014674.SGD","LU0819123356.HKD","LU0516422952.EUR","LU2097828805.USD","LU0823414478.USD","SG9999015945.SGD","SG9999006514.SGD","HYDD.SI","BK1522","BK1610","LU1868837565.USD","LU0320764599.SGD","BK1119","002594","LU0516422440.USD","LU0289739343.SGD","LU0819121731.USD","LU0516423091.SGD","BK1504","LU0214875030.USD","LU0211977185.USD","LU0164872284.USD","00285","SG9999006597.SGD","LU2348774022.SGD","SG9999015978.USD","SG9999015952.SGD","LU2097828714.EUR","LU1808992512.USD","01211","LU0856984785.SGD","LU1861214812.USD","LU0359202008.SGD","LU2360107325.USD","BK1582","LU0823426480.USD","BK1540","LU0588546209.SGD","SG9999001226.SGD","81211","LU0823426308.USD","LU2476274308.USD","BYDDY","LU0516423174.USD","LU0254981946.USD"],"gpt_icon":1},{"id":"2517442945","title":"與復星醫藥“分手”後，靠阿茲夫定成名的真實生物赴港募資","url":"https://stock-news.laohu8.com/highlight/detail?id=2517442945","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517442945?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 23:22","pubTimestamp":1741188171,"startTime":"0","endTime":"0","summary":"3月4日，真实生物发布公告，增设招银国际、华泰金控、申万宏源香港为整体协调人，加上原有整体协调人中金，共有4位整体协调人。这家曾因新冠口服药阿兹夫定一战成名的生物科技公司，如今正深陷业绩下滑与转型阵痛的漩涡。2022年8月，真实生物首次向港交所递表，但产品单一性问题始终无法解决，面对仅剩10个月期限的对赌协议，真实生物再度赴港募资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252317","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1515","BK1191","02196","BK1593"],"gpt_icon":0},{"id":"2517140509","title":"拉來中東土豪，比亞迪在港融資435億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517140509","media":"华尔街见闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517140509?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 21:41","pubTimestamp":1741182075,"startTime":"0","endTime":"0","summary":"全球汽车业“军备竞赛”的缩影。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/3aeed6ba-b9e4-4d54-ac4e-6c5e497099fc.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/3aeed6ba-b9e4-4d54-ac4e-6c5e497099fc.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3742436","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3742436","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["01211","LU2249611893.SGD","LU0588546209.SGD","LU0348767384.USD","LU0449515922.USD","LU0516422952.EUR","SG9999015978.USD","BK1149","BK1515","LU2778985437.USD","SG9999015945.SGD","LU2097828805.USD","LU0516423174.USD","LU0175139822.USD","LU0143863198.USD","HYDD.SI","LU2097828631.EUR","LU2097828557.USD","002594","LU0511384066.AUD","LU0164872284.USD","LU0979878070.USD","LU1242518857.USD","LU1868837565.USD","SG9999014674.SGD","BK1607","LU0516422366.SGD","LU2360107325.USD","00285","LU0449509016.USD","LU0516423091.SGD","SG9999015952.SGD","LU0823414478.USD","LU0359202008.SGD","LU1861219969.SGD","BYDDY","LU0593848301.USD","BK1119","81211","LU0856984785.SGD","BK1540","BK1589","LU2097828714.EUR","BK1509","BK1610","LU0823426308.USD","LU2348774022.SGD","BK1580","SG9999015986.USD","LU0289739343.SGD"],"gpt_icon":1},{"id":"2517913923","title":"恩華藥業(002262.SZ)擬出資350萬美元認購三晟醫藥Pre-A輪優先股1250萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517913923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517913923?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:58","pubTimestamp":1741175893,"startTime":"0","endTime":"0","summary":"本次认购三晟医药Pre-A轮优先股的定价依据系基于公司对三晟医药的在研产品储备、研发实力、未来的发展潜力以及与三晟医药及其子公司未来在产品授权研发及市场化方面的深度合作，在咨询专业机构后，经各方协商一致确认。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0188","BK0239","BK1574","BK1161","BK1515","159938","09939","002262"],"gpt_icon":0},{"id":"2517158009","title":"恩華藥業：擬出資350萬美元購買三晟醫藥Pre-A輪優先股1250萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517158009","media":"视频滚动新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517158009?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:52","pubTimestamp":1741175520,"startTime":"0","endTime":"0","summary":"恩华药业公告，公司拟出资350万美元购买三晟医药的Pre-A轮优先股1250万股，交易完成后公司将持有三晟医药10.448%的股权。三晟医药是一家专注于发现和开发治疗中枢神经系统疾病的创新药物的生物科技公司。此次投资旨在加快创新药物的研发及引进工作，提升公司药物研发效率及市场竞争力，获取新的利润增长点。交易完成后，三晟医药将成为公司的参股公司。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-03-05/doc-inenrcyf7623869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","002262","BK0188","159938","09939","BK0070","BK1574","BK1515","BK0239"],"gpt_icon":0},{"id":"2517543913","title":"授權合作獲益、尚無產品上市，和譽醫藥首度實現全年盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543913","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517543913?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:33","pubTimestamp":1741174410,"startTime":"0","endTime":"0","summary":"和誉医药近日披露2024年业绩，报告期内实现营收5.04亿元，凭借授权款和里程碑付款，尚无产品上市的和誉医药首度实现全年盈利，年内利润为2830.2万元。和誉医药表示，目前有充裕的在手现金储备，现金及银行结余约19.59亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503053337413564.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503053337413564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1161","BK1574","BK1515","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2517903659","title":"白雲山子公司《藥品生產許可證》變更","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903659","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903659?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:53","pubTimestamp":1741172002,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨白云山(00874.HK)公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业核减生产地址及相应的车间生产线、生产范围。明兴药业白云厂区实现规模化运作，本次核减生产车间、生产线和生产范围，有利于进一步整合生产资源、优化产能布局，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185324963a9b73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185324963a9b73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1606","BK1515","00874","BK1197","BK1191"],"gpt_icon":0},{"id":"2517973009","title":"白雲山(00874)：明興藥業收到《藥品生產許可證》","url":"https://stock-news.laohu8.com/highlight/detail?id=2517973009","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517973009?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:52","pubTimestamp":1741171941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，近日，公司子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》，同意明兴药业核减生产地址及相应的车间生产线、生产范围。公告称，明兴药业白云厂区实现规模化运作，本次核减生产车间、生产线和生产范围，有利于进一步整合生产资源、优化产能布局，继续保持稳定的生产能力，满足市场需求。本次获得《药品生产许可证》，对公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0196","BK0239","BK1515","BK1521","BK1606","BK0012","00874","BK0183","BK1191","BK0096","BK0175","BK1197","BK0097","600332","BK0070"],"gpt_icon":0},{"id":"2517299033","title":"白雲山子公司廣藥總院通過高新技術企業重新認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299033","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517299033?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:51","pubTimestamp":1741171909,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨白云山公告，近日，广州白云山医药集团股份有限公司子公司广州医药研究总院有限公司已通过高新技术企业重新认定，并收到由广东省科学技术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高新技术企业证书》。本次广药总院获得《高新技术企业证书》不会对本公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185149a2607f58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305185149a2607f58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00874","BK1197","BK1515","BK1606","BK1521"],"gpt_icon":0},{"id":"2517799732","title":"白雲山(00874)：廣藥總院通過高新技術企業重新認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517799732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517799732?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 18:50","pubTimestamp":1741171812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，该公司子公司广州医药研究总院有限公司(以下简称“广药总院”)已通过高新技术企业重新认定，并收到由广东省科学技术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高新技术企业证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00874","BK0097","BK0239","BK0188","BK1191","BK1515","BK1606","BK0183","600332","BK0012","BK0070","BK0196","BK1521","BK0096","BK1197","BK0028","BK0175"],"gpt_icon":0},{"id":"2517912199","title":"星昊醫藥收盤上漲1.62%，滾動市盈率19.97倍，總市值19.97億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912199","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517912199?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:56","pubTimestamp":1741168562,"startTime":"0","endTime":"0","summary":"3月5日，星昊医药今日收盘16.33元，上涨1.62%，滚动市盈率PE达到19.97倍，创56天以来新低，总市值19.97亿元。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均45.51倍，行业中值26.30倍，星昊医药排名第69位。资金流向方面，3月5日，星昊医药主力资金净流入139.66万元，近5日总体呈流入状态，5日共流入1042.52万元。最新一期业绩显示，2024年三季报，公司实现营业收入4.68亿元，同比-9.91%；净利润7877.01万元，同比8.22%，销售毛利率69.38%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/05175648542748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","159938","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2517999931","title":"國家醫保局：國家醫保信息平台累計歸集追溯碼227億條","url":"https://stock-news.laohu8.com/highlight/detail?id=2517999931","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517999931?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:37","pubTimestamp":1741167430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09939","BK1161","BK1574","BK1515","159938"],"gpt_icon":0},{"id":"2517996020","title":"石藥(01093.HK)：新藥JMT108獲批於中國開展臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996020","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996020?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:25","pubTimestamp":1741166700,"startTime":"0","endTime":"0","summary":"石药集团(01093.HK) 公布，由集团开发的一类新药双功能融合蛋白药物JMT108，已获国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，本次获批的临床适应症为晚期恶性肿瘤。集团表示，临床前研究显示该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531121548386_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422393/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0880133367.SGD","LU0072913022.USD","LU0067412154.USD","LU1960683339.HKD","LU1226287875.USD","LU1951186391.HKD","IE0008368742.USD","IE00BZ08YT58.USD","SG9999004220.SGD","LU1807302812.USD","01093","LU0326950275.SGD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1008478684.HKD","LU1226287792.SGD","LU0501845795.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","03347","BK1141","IE00BZ08YR35.GBP","BK1521","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","BK1583","LU1226288170.HKD","LU1226287529.USD","BK1191","IE00B5MMRT66.SGD","LU1226288253.USD","LU1152091754.HKD","BK1576"],"gpt_icon":0},{"id":"2517299674","title":"石藥集團(01093)開發的I類新藥雙功能融合蛋白藥物JMT108獲中國臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299674","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517299674?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 17:22","pubTimestamp":1741166538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，该集团开发的I类新药双功能融合蛋白药物JMT108已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。临床前研究显示，该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","LU1226287875.USD","LU1807302812.USD","LU1226288253.USD","LU0880133367.SGD","LU1152091168.USD","BK1191","BK1576","IE00BZ08YS42.EUR","01093","SG9999004220.SGD","LU0072913022.USD","LU1226287792.SGD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00B543WZ88.USD","BK1583","BK1141","LU0501845795.SGD","LU1226288170.HKD","LU1951186391.HKD","BK1521","LU0140636845.USD","LU0067412154.USD","LU1960683339.HKD","LU1226287529.USD","IE0008369823.USD","LU1008478684.HKD","03347","IE00B5MMRT66.SGD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1993786604.SGD","BK1515"],"gpt_icon":0}],"pageSize":16,"totalPage":37,"pageCount":10,"totalSize":579}]}}